🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨Latest paper just hit in JNM 🚨 It's got... ✅Single domain Antibodies. ✅PET imaging. ✅#LiverCancer Buckle up! Thread time. 🧵 1/x jnm.snmjournals.org/content/early/…

Honored to visit the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and speak about our studies of glypicans and other CAR-T targets in solid tumors. UPMC @NCIResearchCtr

Dr Dan Li Dan Li @NCIResearchCtr Eureka Therapeutics is presenting our poster on newly engineered CAR-T cells based on gamma/delta TCR platform targeting glypicans in solid tumors AACR #AACR24

Very proud of Dr Dan li Dan Li, who received “Outstanding Postdoctoral Fellow Award” from Dr. Douglas R. Lowy National Cancer Institute. She presented our new development of camel nanobodies and CAR-T cells targeting B7-H3 for treating cancer at CCR FYI Colloquium @NCI_Training @NCIResearchCtr

Traveled to Beijing this week to give a keynote lecture at the Advanced Therapies Beijing Summit 2024. Had a great discussion with companies about collaborating on developing new cell therapies for treating liver cancer and other solid tumors.@NCIResearchCtr

I am happy to share the latest review on cancer therapy with antibodies Nature Reviews Cancer @NCIResearchCtr. It was a pleasure to be part of the team led by Suman Paul and Shibin Zhou Johns Hopkins University

So proud of Laura Hutchins, a postbaccalaureate fellow in our lab @NCIResearchCtr NIH Office of Intramural Training & Education, who was selected to give a talk #PEGSummit PEGS Summit for her work on a new antibody-directed TCR targeting GPC2 for treating neuroblastoma.

Our new study demonstrates that combination of an engineered IL-7 and CAR-T cells targeting GPC3, GPC2, and Mesothelin can greatly enhance anti-tumor activity in liver cancer, pediatric cancer and ovarian cancer. @NCIResearchCtr NeoImmuneTech Dan Li

CAR T cells based on our humanized rabbit monoclonal antibody, called hYP218, targeting mesothelin epitope close to cell membrane, are very effective against mesothelin-positive tumors. @NCIResearchCtr NIH Clinical Center

Let’s take a closer look at recent #JITC article: “rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors” by Mitchell Ho, PhD & Dan Li from @NCIResearchCtr & NeoImmuneTech. 1/8

Honored and humbled to receive the Asian American Engineer of the Year award. Will be giving a lecture on engineering antibodies and T cells to target glypicans in cancer. #AAEOY @NCIResearchCtr

Happy to share our new research paper. We report for the first time the discovery of molecular interaction between GPC3 and AFP, both of which are specific proteins associated with liver cancer. ⁦@NCIResearchCtr⁩ ⁦National Cancer Institute⁩ ⁦NIH Intramural⁩ onlinelibrary.wiley.com/doi/10.1002/pg…

Glad to share our new paper describing the discovery of a camel nanobody that mimics a TCR targeting the pMHC complex derived from an intracellular HPV tumor antigen and the generation of CAR-T cells against cervical cancer. Christian Hinrichs @NCIResearchCtr NIH Intramural

Fantastic opening session “Bench To Bedside: Emerging Therapeutic Targets” #ILCA24 by Valerie Chew @TimGreten Dr Greten and I discussed basic and clinical research on liver cancer immunotherapy @NCIResearchCtr NIH Intramural

Proud to listen to Dr Dan Li Dan Li present our work on engineering T cells to target GPC3 in HCC at #ILCA24. @NCIResearchCtr NIH Intramural @NCI_Training

Register today for the Sixth Annual Pelotonia Institute for Immuno-Oncology (#PIIO) Symposium! go.osu.edu/io2024 Dec 2-3, Vitria on the Square, 14 E. 15th Ave, 2nd Floor, Columbus, OH 43201 (across from Ohio Union)

Honored to give a lecture at the Annual Meeting of the Pelotonia Institute of ImmunoOncology at Ohio State University Pelotonia Institute for Immuno-Oncology The James Zihai Li, MD, PhD NIH Intramural National Cancer Institute

It has been a great day! Thank you for inviting me to meet with wonderful faculty members and students at OSU and give a lecture at the Annual Meeting of the Pelotonia Institute of ImmunoOncology. Pelotonia Institute for Immuno-Oncology National Cancer Institute NIH NIH Intramural

🥳 Our 2nd most downloaded article in 2024: Cancer therapy with antibodies by Paul, Gabelli, Mitchell Ho, PhD, van Elsas & colleagues bit.ly/4hXKvnw John Hopkins National Cancer Institute NIH Cancer at Nature Portfolio #NRCtop10of2024

I discuss the urgent crisis from the loss of federal support of science in the US and recent clinical gene editing breakthroughs with Walter Isaacson & Christiane Amanpour on Amanpour and Company, airing on PBS tonight at 11 pm ET, and on CNN International earlier today. Pls share! youtube.com/watch?v=8YhJM6…